Empowered Funds
AARD icon

Empowered Funds’s Aardvark Therapeutics AARD Stock Holding History

Empowered Funds’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$124K Buy
+23,602
New +$144K ﹤0.01% 2383

Other funds holding AARD

Decheng Capital
Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Empowered Funds's AARD Position: Q3 2026 in Review

Empowered Funds opened a new position in Aardvark Therapeutics (AARD) in Q3 2026: 23,602 shares worth $124K. The stake represents ﹤0.01% of the portfolio and ranks #2383 among its holdings.

50 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Empowered Funds held 23,602 shares of Aardvark Therapeutics worth $124K as of Q3 2026.
  • Aardvark Therapeutics was a new Empowered Funds position in Q3 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2383 holding.
  • 50 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.